X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate the ability of RLS-0071, a novel 15 amino acid peptide dual-targeting anti-inflammatory inhibitor of complement and neutrophil effectors, to mitigate the gastrointestinal effects of ARS (GI-ARS) in a preclinical mouse model.
Lead Product(s): RLS-0071
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: RLS-0071
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: ReAlta Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2024
Details:
The funding will support preclinical studies evaluating the breadth of protection and immune response induced by the company’s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.
Lead Product(s): OVX836
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Osivax
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 05, 2023
Details:
OCU500 is a mucosal vaccine candidate which is delivered via two different mucosal routes, inhalation into the lungs and as a nasal spray, which is investigated for the treatment of COVID-19 and influenza (flu).
Lead Product(s): OCU500
Therapeutic Area: Infections and Infectious Diseases Product Name: OCU500
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Ocugen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
The funding will be used to conduct nonclinical and clinical studies to advance its pan-coronavirus protease inhibitor ALG-097558, a potent, pan-coronavirus small molecule inhibitor of the viral 3CL protease, into future Phase 2/3 studies.
Lead Product(s): ALG-097558
Therapeutic Area: Infections and Infectious Diseases Product Name: ALG-097558
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Aligos Therapeutics
Deal Size: $8.5 million Upfront Cash: Undisclosed
Deal Type: Funding October 03, 2023
Details:
The funding will be used for the development of a Group B Streptococcus vaccine using Omniose bioconjugate vaccine platform which enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within E. coli cell.
Lead Product(s): GBS Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Recipient: Omniose
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 27, 2023
Details:
The funding will be used to develop RVB-101, a genetically engineered cell therapy within a moisturizer formulation for the treatment for severe atopic dermatitis.
Lead Product(s): RVB-101
Therapeutic Area: Dermatology Product Name: RVB-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: ResVita Bio
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding September 18, 2023
Details:
The agreement aims to evaluate the immunogenicity and efficacy of two IMUNON DNA-based Lassa virus vaccine candidates. NIAID will assess the efficacy of PlaCCine DNA constructs against Lassa virus in guinea pig and non-human primate disease models.
Lead Product(s): DNA-based Lassa Virus Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Imunon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2023
Details:
The proceeds will be used to advance XVIR-110, an ultra-long-acting HIV integrase inhibitor with a preclinical profile that suggests best-in-class potential for HIV pre-exposure prophylaxis, and for HIV treatment as the cornerstone of a next-generation multi-drug regimen.
Lead Product(s): XVIR-110
Therapeutic Area: Infections and Infectious Diseases Product Name: XVIR-110
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Exavir Therapeutics
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 22, 2023
Details:
The proceeds will be used for the preclinical development of Trethera’s first-in-class small molecule, TRE-515, an orally delivered, therapeutic engineered to inhibit dCK, for the treatment of acute disseminated encephalomyelitis, which holds the FDA Orphan Drug designation.
Lead Product(s): TRE-515
Therapeutic Area: Immunology Product Name: TRE-515
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Trethera
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 14, 2023
Details:
The net funding will be used to advance the development of its PLX-R18 cell therapy as a potential novel treatment for Hematopoietic Acute Radiation Syndrome (H-ARS).
Lead Product(s): PLX-R18
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PLX-R18
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Pluri
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Funding July 11, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
